Locust Walk Insights

LOCUST WALK INSIGHTS

A Brave New World: Japan Pharma and COVID-19

COVID-19 or SARS Cov-2 to be precise, has changed the world in many regards. From the way we work, to the way we do business as well as to even what used to be the simplest thing – chatting over coffee. Now everything, or at least for the time being, is either via...

Panel Recording on 6.11: Accessing Capital in the Time of COVID

Danforth Advisors, Locust Walk, and Mintz joined on Thursday, June 11th from 2-3pm EST for the panel, "Accessing Capital in the Time of COVID: Challenges, Opportunities, and Best Practices." During the hour, the panel discussed How COVID-19 impacted the capital...

Q1 2020 Report: Global Trends in Biopharma Transactions

Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our Q1 2020 Report: Global Trends in Biopharma Transactions applies the latest data to analyze current activities in the life science deal...

LIVE Panel Discussion: Q1 2020 Biopharma Market Conditions

Please join us Thursday, April 16th from 2-3 pm EST where our team will dive into Q1 2020 market conditions with a lens on partnerships, financings, and insight into current and future trends. We will be releasing our Q1 2020 bipopharma market conditions report in...

LIVE Panel Discussion, COVID-19: Strategic Implications on Biopharma

Please join us Thursday, April 2nd from 1-2 PM EST to listen to the LIVE panel, COVID 19: Strategic Implications on Biopharma. Following our COVID-19 thought leadership piece on the strategic implications for biopharma, our panelists look forward to taking a deeper...

Strategic Implications of COVID-19 on Biopharma

These are challenging times for governments, public health administrations and the financial markets. While each biopharma company's primary concern is the health and safety of its team members, the industry also a responsibility to the world to take an active role in...

Deal Makers of Japan, Volume 1

Locust Walk has been active in Asia, in particular, Japan for nearly half of the firm’s history and we are deeply rooted in the market. We have advised on more than a dozen transactions during our history in Japan and have successfully helped deal making between US/EU...

2019 Year End Review Biopharma Report

Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2019 Annual Report: Global Trends in Biopharma Transactions applies the latest data to analyze current activities in the life sciences deal...

2019 Medtech Year End Review Report

Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our Medtech 2019 Annual Report: Global Trends in Medtech Transactions applies the latest data to analyze current activities in the medtech deal...